A new study published in BMC Pregnancy and Childbirth aimed to determine the prevalence of group B Streptococcus (GBS) colonization, antimicrobial susceptibility patterns and to assess risk factors among pregnant women. This was a prospective cross-sectional study conducted from May to August 2014 at selected public antenatal care (ANC) centers. The study involved the collection of 281 lower vaginal swabs and inoculation into 1 ml Todd Hewitt Broth supplemented with gentamicin and nalidixic acid to prevent the growth of contaminants. After overnight incubation, all broths were sub-cultured on 5% sheep blood agar for isolation of GBS. Antimicrobial susceptibility testing was performed according to the criteria of the Clinical and Laboratory Standard Institute (CLSI) guidelines 2013.The results revealed that the overall prevalence of GBS colonization among pregnant women was 14.6%. Group B Streptococcus colonization could be markedly correlated to health institutions. Meanwhile, all GBS isolates were susceptible to chloramphenicol. On the other hand, resistance to tetracycline, cefotaxime, clindamycin, penicillin, vancomycin, ampicillin and erythromycin was 90.2%, 34.1%, 26.8%, 19.5%, 17%, 14.6% and 7.5% respectively. Further, multidrug resistance was detected in 43.9% of the isolates. The findings suggested a high frequency of GBS colonization (14.6%) and resistance to the commonly used antibiotics which emphasizes upon the importance of the screening of GBS colonization in pregnant women at 35-37 weeks of gestation and testing their antimicrobial susceptibilities in order to provide antibiotic prophylaxis and minimize newborn infection and co-morbidity.